Paragon Care Limited (PGC) AI Stock Analysis

• Market Cap: AU$471.76M
• Dividend Yield: N/A
• Average Volume (3M): 412.10K
• Price to Earnings (P/E): 22.6
• Beta (1Y): 1.37
• Revenue Growth: 21.68%
• EPS Growth: 37.78%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): <0.01
• Shares Outstanding: 1,655,305,400
• 10 Day Avg. Volume: 398,881
• 30 Day Avg. Volume: 412,096
• PEG Ratio: 0.78
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.17
• P/FCF Ratio: -26.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.50
• Price Target Upside: 78.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 46 Neutral
• Price Target: AU$0.50 ▲(78.57% Upside)

Paragon Care Limited's overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The company's moderate valuation provides some support, but the lack of dividend yield and negative market momentum weigh heavily on the score.

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.

How the Company Makes Money

Paragon Care Limited generates revenue through the sale of medical equipment and consumables to healthcare providers, including hospitals and medical facilities. The company has a diverse product portfolio, enabling it to cater to various segments within the healthcare industry. In addition to product sales, Paragon Care also offers maintenance and repair services for medical equipment, providing an additional revenue stream. Strategic partnerships with manufacturers and healthcare providers further enhance the company's market position and contribute to revenue growth. The company's focus on innovation and quality assurance helps maintain its competitive edge in the medical supply industry.

Paragon Care Limited Financial Statement Overview

Summary

Paragon Care Limited is facing a challenging financial environment with declining revenue and low profitability margins. Despite some operational efficiency gains, the company struggles with cash flow management and moderate leverage, indicating financial instability.

Income Statement

Paragon Care Limited has experienced a significant decline in revenue growth, with a negative growth rate of -22.46% in the most recent year. The gross profit margin is relatively low at 8.97%, indicating limited profitability from core operations. The net profit margin is also low at 0.57%, reflecting challenges in converting revenue into profit. However, there is a slight improvement in EBIT and EBITDA margins compared to previous years, suggesting some operational efficiency gains.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.93, indicating a balanced approach to leveraging. Return on equity is modest at 6.45%, showing some ability to generate returns for shareholders. The equity ratio stands at 25.84%, suggesting a reasonable proportion of assets financed by equity. Overall, the balance sheet reflects moderate financial stability with manageable leverage.

Cash Flow

Paragon Care Limited faces challenges in cash flow management, with negative operating cash flow and free cash flow in the latest period. The free cash flow growth rate is high at 687.12%, but this is from a negative base, indicating volatility. The operating cash flow to net income ratio is negative, highlighting difficulties in converting accounting profits into cash. The free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.61B	3.61B	2.97B	307.63M	237.62M	235.84M
Gross Profit	324.00M	324.00M	176.07M	51.68M	36.58M	33.41M
EBITDA	89.81M	89.81M	43.18M	37.07M	23.96M	26.54M
Net Income	20.57M	20.57M	8.38M	12.80M	6.63M	8.28M
Balance Sheet
Total Assets	1.23B	1.23B	1.13B	448.52M	438.44M	291.92M
Cash, Cash Equivalents and Short-Term Investments	21.90M	21.90M	19.94M	970.00K	46.20M	33.20M
Total Debt	296.52M	296.52M	251.83M	122.14M	131.26M	113.01M
Total Liabilities	915.04M	915.04M	838.97M	196.56M	196.31M	170.40M
Stockholders Equity	319.00M	319.00M	291.92M	18.88M	235.82M	121.52M
Cash Flow
Free Cash Flow	-23.04M	-23.04M	25.14M	-3.30M	14.42M	22.18M
Operating Cash Flow	-11.35M	-11.35M	44.45M	17.75M	19.03M	27.46M
Investing Cash Flow	-16.64M	-16.64M	-19.52M	-31.75M	7.07M	-18.80M
Financing Cash Flow	28.65M	28.65M	-5.95M	-10.00M	-11.93M	32.00K

Paragon Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.34, and below the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 31.71 is Neutral, neither overbought nor oversold. The STOCH value of 19.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	70 Outperform	AU$489.48M	14.58	18.59%	5.06%	6.73%	37.16%
SIG	53 Neutral	€33.30B	57.31	-1.63%	0.43%	45.73%	-231.34%
HLS	53 Neutral	€591.80M	―	-67.21%	―	-23.02%	33.11%
BOT	53 Neutral	AU$305.45M	―	-90.93%	―	456.50%	-457.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PGC	46 Neutral	AU$471.76M	22.58	6.74%	―	21.68%	37.78%
MYX	46 Neutral	$474.48M	―	-21.13%	―	5.07%	46.14%

Paragon Care Limited Corporate Events

Paragon Care to Announce FY25 Financial Results on 27 August

Paragon Care Limited has announced that it will release its full-year financial results for the period ending 30 June 2025 on 27 August 2025. A conference call for investors and analysts will be held on the same day, hosted by the company’s leadership team, to discuss the results. This announcement indicates Paragon Care’s commitment to transparency and engagement with its stakeholders, potentially impacting investor confidence and market positioning.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Limited Announces Director’s Acquisition of Performance Rights

Paragon Care Limited announced a change in the director’s interest, with Carmen Riley acquiring 2,247,877 Performance Rights, as approved in the company’s Annual General Meeting on November 21, 2024. This change reflects the company’s ongoing commitment to aligning its leadership’s interests with its strategic goals, potentially impacting its market positioning and stakeholder confidence positively.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Director Increases Shareholding

Paragon Care Limited has announced a change in the director’s interest, with Director Carmen Riley acquiring an additional 138,888 ordinary shares through an on-market trade. This acquisition increases Riley’s total holdings to 438,888 ordinary shares, which may indicate confidence in the company’s future performance and could impact investor perceptions positively.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Appoints Carmen Riley as New CEO

Paragon Care Limited has announced the appointment of Carmen Riley as the new Chief Executive Officer, effective July 1, 2025. This transition follows the successful merger of Oborne, ParagonCare, and Clifford Hallam Healthcare Pty Ltd (CH2), and aligns with the company’s long-term growth strategy. Carmen Riley, who has been with CH2 for 15 years and served as Chief Operating Officer, will take over from David Collins, who will remain as Managing Director until June 2026. This leadership change is expected to bolster Paragon Care’s growth prospects and enhance shareholder equity, with David Collins focusing on mergers and acquisitions during the transition period.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.

Paragon Care Limited Announces Change in Substantial Holder Voting Power

Paragon Care Limited has reported a change in the voting power of its substantial holder, Wilson Asset Management Group, which has increased from 6.19% to 7.45%. This change in voting power indicates a shift in the control dynamics within the company, potentially impacting decision-making processes and stakeholder interests.

The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.